GS Pharma SRL
2.0 FTEThe score of GS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +17 % Total assets -1 % Headcount (avg FTE) +11 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
GS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 124,005 € | ||||
| Equity | 148,356 € | ||||
| Cash | 17,075 € | ||||
| EBITDA | 158,877 € | ||||
| Total assets | 796,930 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jun 2026
- Year ended 31 Dec 2024filed on 16 Oct 2025
- Year ended 31 Dec 2023filed on 28 Aug 2024
- Year ended 31 Dec 2022filed on 26 Jul 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
GS Pharma's financial analysis
- Solvency18.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of GS Pharma
GS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0848.422.277
- VAT number
- BE0848422277
- Peppol
- Registered · 0208:0848422277 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Sep 2012
- Registered office
- 1702 Dilbeek
- Size
- Micro · 2.0 FTE
- Latest accounts
- 2025 · filed on 20 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
GS Pharma (SRL) has been based in Dilbeek since 2012, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 124,005 € and equity of 148,356 €; its revenue is not published. With 2.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 18.6%, below the median of its sector (44.2%).
Companies similar to GS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmachim Retail sale of pharmaceutical products Seraing · balance sheet 797,111 €
- Pharmacie Goffin Gray Retail sale of pharmaceutical products Etterbeek · balance sheet 798,770 €
- Apotheek Schelfhout Retail sale of pharmaceutical products Evergem · balance sheet 798,974 €
- Cobra Apotheek Centrum Retail sale of pharmaceutical products Mol · balance sheet 791,276 €
- Gooreind Pharma Retail sale of pharmaceutical products Wuustwezel · balance sheet 791,241 €
- Paal Farma Retail sale of pharmaceutical products Beringen · balance sheet 790,795 €
- Dr. Apr. D. Kieffer Retail sale of pharmaceutical products Hasselt · balance sheet 790,139 €
- Zoniapharma Retail sale of pharmaceutical products Sint-Genesius-Rode · balance sheet 804,389 €
Frequently asked questions about GS Pharma
What is the revenue of GS Pharma?
GS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of GS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0848422277 for GS Pharma, if the company is VAT-registered. Its company number (CBE) is 0848.422.277.
Where is the registered office of GS Pharma?
According to the CBE register, the registered office of GS Pharma is in 1702 Dilbeek.
What is the equity of GS Pharma?
At the close of the 2025 financial year, the equity of GS Pharma amounts to 148,356 €, a solvency of 18.6% of total assets.
How many people work at GS Pharma?
2.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages GS Pharma?
The register lists 2 active mandates at GS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of GS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →